SCHEMBL6469680

SCHEMBL6469680

COc1ccc(-c2nc(-c3ccncc3)c(-c3ccc(Cl)cc3)[nH]2)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 10/20 0.69
MAPK12 P53778 10/20 0.69
MAPK11 Q15759 10/20 0.69
MAPK14 Q16539 10/20 0.69
GCGR P47871 10/20 0.69
RAF1 P04049 2/20 0.63
MAPT P10636 3/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
NOX1 Q9Y5S8 1/20 0.55
TP53 P04637 1/20 0.55
THRB P10828 1/20 0.55
ALOX5 P09917 1/20 0.55
MPO P05164 1/20 0.54
SMPD3 Q9NY59 2/20 0.53
MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6466475 0.90 NOX1 (0.71) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL6465030 0.89 MAPK13 (0.71) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL6449315 0.88 MAPK11 (0.72) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL28221004 0.86 MAPT (0.56) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL2649944 0.85 MAPK13 (0.64) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL5196177 0.84 MAPK13 (0.64) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL15075623 0.84 MAPK13 (0.71) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL6164173 0.84 MAPK13 (0.79) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL6469323 0.84 MAPK13 (0.79) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL6467858 0.83 MAPK14 (0.74) MAPK13MAPK12MAPK11MAPK14GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections AXXIMA PHARMACEUTICAL AG. (DE) 2005-09-15 US claimed
US-20240000821-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER UNIV JOHNS HOPKINS (US) 2024-01-04 US disclosed
US-20200078387-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY 2020-03-12 US disclosed
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections AXXIMA PHARMACEUTICAL AG. (DE) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections CSNK1G1, CSNK1E, CSNK1D MAPK13 456/4885MAPK12 732/4885MAPK11 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.